Introduction

#

If you have spent any time researching longevity supplements, you have almost certainly encountered the NMN versus NR debate. These two molecules — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are the most popular NAD+ precursors on the market, and both promise to replenish a coenzyme that declines steadily as you age. That decline in NAD+ is now recognized as one of the central mechanisms of aging itself, linked to everything from mitochondrial dysfunction and DNA damage accumulation to metabolic slowdown and cognitive decline.

The problem is that choosing between NMN and NR is not straightforward. NMN has captured enormous public attention thanks to Harvard geneticist Dr. David Sinclair, whose personal supplementation protocol and animal research have made NMN a household name in the biohacking community. NR, on the other hand, has the backing of ChromaDex and its consumer brand Tru Niagen, with over 40 published clinical studies and a robust intellectual property portfolio of 90+ patents. Both raise NAD+ levels. Both have clinical trial data in humans. But the devil is in the details — and those details matter if you are spending your money on one of these supplements every month.

This guide breaks down everything you need to know: the science of NAD+ decline, how each molecule works, the Slc12a8 transporter controversy, what human clinical trials actually show, bioavailability differences, the FDA regulatory saga around NMN, dosing protocols, side effects, cost analysis, and which supplement makes the most sense for your situation. Every claim is backed by published research with real PubMed citations so you can verify the evidence yourself.

Watch Our Video Review

#

The NAD+ Crisis: Why This Matters for Aging

#

What Is NAD+ and Why Does It Decline?

#

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It serves two critical functions: it acts as an electron carrier in metabolic reactions (particularly in mitochondrial energy production), and it serves as a substrate for enzymes that regulate DNA repair, gene expression, and cellular stress responses.

The enzymes that consume NAD+ as a substrate include:

• Sirtuins (SIRT1-7): Often called “longevity genes,” sirtuins regulate DNA repair, inflammation, mitochondrial biogenesis, and metabolic health. They are NAD+-dependent deacetylases, meaning they cannot function without adequate NAD+ levels (Imai and Guarente, 2014; PMID: 24560926).
• PARPs (poly-ADP-ribose polymerases): These enzymes detect and repair DNA damage. PARP1 is one of the largest consumers of cellular NAD+, and its activity increases with age as DNA damage accumulates.
• CD38: An ectoenzyme that degrades NAD+ and is increasingly recognized as a major driver of age-related NAD+ decline.

Here is the central problem: NAD+ levels drop by approximately 50% between the ages of 40 and 60 in multiple tissues, including the brain, liver, muscle, and skin. This decline has been documented in both animal models and human studies (Zhu et al., 2015; PMID: 26458459). By the time you are 80, your NAD+ levels may be a fraction of what they were in your 20s.

CD38: The NAD+ Destroyer

#

A landmark 2016 study by Camacho-Pereira et al. published in Cell Metabolism identified CD38 as the primary enzyme responsible for age-related NAD+ decline (PMID: 27304511). The researchers showed that CD38 expression and activity increase dramatically with aging, and that CD38 knockout mice are protected from age-related NAD+ loss and mitochondrial dysfunction.

What makes this finding particularly important is that CD38 does not just consume NAD+ — it also degrades NMN, the immediate precursor to NAD+. This means that rising CD38 activity with age creates a double problem: it destroys existing NAD+ and intercepts the raw materials your body needs to make more.

This discovery has fueled interest in CD38 inhibitors as a complementary strategy to NAD+ precursor supplementation. The flavonoids apigenin and quercetin have been identified as natural CD38 inhibitors. A 2013 study by Escande et al. in Diabetes demonstrated that apigenin inhibits CD38 activity, increases intracellular NAD+ levels, and activates sirtuin-mediated deacetylation in cell culture models (PMID: 23172919). This is one reason why some longevity protocols stack apigenin or quercetin with NMN or NR — the idea is to simultaneously boost NAD+ production while reducing its destruction.

The Downstream Consequences of NAD+ Decline

#

When NAD+ falls, the consequences cascade through multiple systems:

• Mitochondrial dysfunction: Less NAD+ means less efficient electron transport chain activity, reduced ATP production, and increased reactive oxygen species (ROS) generation.
• Impaired DNA repair: Sirtuins and PARPs compete for the shrinking NAD+ pool. As NAD+ drops, DNA damage accumulates faster than it can be repaired.
• Metabolic dysfunction: NAD+ depletion contributes to insulin resistance, fatty liver disease, and weight gain.
• Neurodegeneration: Brain tissue is particularly sensitive to NAD+ depletion, and declining levels are associated with cognitive decline, Alzheimer’s disease, and Parkinson’s disease.
• Chronic inflammation: Reduced sirtuin activity leads to increased NF-kB signaling and a pro-inflammatory state sometimes called “inflammaging.”

This is the foundational science behind both NMN and NR supplementation: if NAD+ decline drives aging, then replenishing NAD+ through precursor supplementation could theoretically slow or partially reverse multiple aspects of the aging process.

What Is NMN (Nicotinamide Mononucleotide)?

#

The Molecule

#

NMN is a nucleotide composed of nicotinamide (a form of vitamin B3), a ribose sugar, and a phosphate group. Its molecular weight is 334.22 g/mol. In the NAD+ biosynthesis pathway, NMN sits one step away from NAD+ — the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) converts NMN directly into NAD+ by adding an adenylyl group.

This “one step away” position in the pathway is a key selling point for NMN advocates. The argument is that by supplementing with NMN rather than earlier precursors like niacin or niacinamide, you bypass the rate-limiting step catalyzed by NAMPT (nicotinamide phosphoribosyltransferase), which slows down with age.

How NMN Enters Cells: The Slc12a8 Debate

#

One of the most contested questions in NAD+ biology is whether NMN can enter cells directly or must first be broken down to NR for cellular uptake. This matters because NMN is a relatively large, charged molecule due to its phosphate group, which in theory should prevent it from crossing cell membranes easily.

In 2019, Grozio et al. from Shin-ichiro Imai’s lab at Washington University published a landmark study in Nature Metabolism claiming to have identified Slc12a8 as a specific NMN transporter (PMID: 31131364). The researchers reported that Slc12a8 is highly expressed in the murine small intestine, specifically transports NMN (but not NR), and that its expression is upregulated with aging as a compensatory response to falling NAD+ levels. Slc12a8 knockout mice showed significantly decreased NAD+ levels in the jejunum and ileum.

However, this finding was immediately challenged. Schmidt and Brenner published a rebuttal in Nature Metabolism arguing that the analytical methods and transport data did not support NMN transport by Slc12a8 (PMID: 32694648). They contended that NMN is dephosphorylated to NR by the extracellular enzyme CD73 before cellular uptake, and that what appears to be direct NMN transport may actually reflect rapid extracellular conversion to NR followed by NR import through equilibrative nucleoside transporters (ENTs).

A subsequent triple-isotope tracing study added further complexity, observing less than 1% NMN uptake in the intestine after oral administration, which is difficult to reconcile with high Slc12a8 expression in those tissues (Chellappa et al., 2023; PMID: 37445041).

The current scientific consensus is unsettled. The Slc12a8 transporter may play a real but limited role in NMN uptake, particularly in the gut. However, a significant portion of orally consumed NMN appears to be converted to NR before entering systemic circulation. For practical purposes, both pathways likely contribute, and supplemental NMN does effectively raise blood and tissue NAD+ levels regardless of the precise mechanism of entry.

David Sinclair and the NMN Movement

#

No discussion of NMN is complete without mentioning Dr. David Sinclair, a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. Sinclair’s research on sirtuins and NAD+ has been foundational to the longevity field, and his personal supplementation protocol — which includes 1 gram of NMN daily alongside 1 gram of resveratrol — has arguably done more to popularize NMN than any clinical trial.

Sinclair’s rationale for combining NMN with resveratrol is mechanistically elegant: resveratrol activates SIRT1 (the most-studied sirtuin), while NMN provides the NAD+ fuel that SIRT1 needs to function. He has described this as providing both the “accelerator” (resveratrol) and the “fuel” (NAD+ via NMN) for the sirtuin pathway.

His 2013 paper in Cell demonstrated that NMN could reverse aspects of aging in mice, improving mitochondrial function, insulin sensitivity, and physical endurance in older animals (Gomes et al., 2013; PMID: 24331606). His 2020 paper showed that NAD+ replenishment could restore blood vessel growth and muscle endurance in aged mice (Das et al., 2018; PMID: 29570999).

It is important to note that while Sinclair’s animal research is compelling, he has financial interests in longevity companies, which some critics argue should temper public enthusiasm about NMN until more human clinical trials are completed. That said, his research has been published in top-tier journals and has been independently replicated by other labs.

What Is NR (Nicotinamide Riboside)?

#

The Molecule

#

NR is a pyridine-nucleoside form of vitamin B3 with a molecular weight of 255.25 g/mol — notably smaller than NMN because it lacks the phosphate group. NR was first described as a NAD+ precursor in yeast by Bieganowski and Brenner in 2004 (PMID: 15137942), and Charles Brenner has since become one of the most prominent advocates for NR over NMN.

In the NAD+ biosynthesis pathway, NR requires two enzymatic steps to become NAD+:

1. NR kinases (NRK1/NRK2) phosphorylate NR to produce NMN.
2. NMNAT enzymes then convert NMN to NAD+.

This means that NR is technically two steps away from NAD+, while NMN is one step away. NMN advocates argue this makes NMN more efficient, while NR advocates counter that the extra step is not rate-limiting and that NR’s superior cell permeability more than compensates.

How NR Enters Cells

#

Unlike NMN, the cellular uptake mechanism for NR is well-established and not controversial. NR enters cells through equilibrative nucleoside transporters (ENTs), the same family of transporters used by nucleosides like adenosine. Because NR lacks the charged phosphate group that NMN carries, it crosses cell membranes efficiently.

Once inside the cell, NR is phosphorylated by NR kinase 1 or NR kinase 2 (NRK1/NRK2) to form NMN, which is then converted to NAD+ by NMNAT enzymes. This intracellular conversion pathway has been verified in multiple studies and is not disputed.

ChromaDex, Tru Niagen, and the NR Industry

#

The NR supplement market is dominated by ChromaDex (now operating as Niagen Bioscience), which holds the patent on nicotinamide riboside chloride (NRC) under the trade name Niagen. Their consumer product, Tru Niagen, is the most widely sold NR supplement globally.

ChromaDex’s competitive moat is substantial:

• 90+ owned and licensed patents protecting Niagen and other NAD+ precursors
• 40+ published clinical studies using their patented NR ingredient
• Niagen is used in 65% of all registered NR clinical trials, giving them an outsized share of the evidence base
• FDA-notified New Dietary Ingredient (NDI) status with a clean regulatory record
• Pharmaceutical-grade Niagen+ for IV and injectable use, launched in 2024 for clinical settings

The company has also secured an exclusive license to develop NR as a potential Parkinson’s disease therapy in collaboration with Haukeland University Hospital in Norway, where the Phase III NOPARK trial is enrolling 400 participants at 1,000 mg NR daily for 52 weeks.

This institutional backing gives NR a significant advantage in terms of quality control and standardization. When you buy Tru Niagen, you know exactly what you are getting. The NMN market, by contrast, is fragmented among dozens of brands with varying purity and no single dominant patent holder.

Head-to-Head: NMN vs NR Compared

#

NAD+ Biosynthesis Pathways

#

To understand how NMN and NR compare, it helps to see where they fit in the broader NAD+ biosynthesis landscape. There are three major pathways:

1. De novo synthesis (from tryptophan): The kynurenine pathway converts the amino acid tryptophan into NAD+ through multiple enzymatic steps. This is the most “expensive” pathway metabolically and is primarily active in the liver.

2. Preiss-Handler pathway (from niacin/nicotinic acid): Niacin is converted to nicotinic acid mononucleotide (NaMN), then to nicotinic acid adenine dinucleotide (NaAD), and finally to NAD+. This pathway is effective but can cause the notorious “niacin flush” — an uncomfortable skin flushing caused by prostaglandin release.

3. Salvage pathway (from nicotinamide, NR, and NMN): This is the most important pathway for maintaining cellular NAD+ levels. Nicotinamide (niacinamide) is converted to NMN by the rate-limiting enzyme NAMPT. NR is converted to NMN by NR kinases. NMN is then converted to NAD+ by NMNAT. Both NMN and NR supplements enter this pathway, but at different points.

The critical difference: NMN supplementation bypasses the NAMPT bottleneck entirely, delivering NMN directly. NR supplementation also bypasses NAMPT by entering through a parallel route (NR kinases). Both avoid the rate-limiting step — they just take different doors into the same room.

Comprehensive Comparison Table

#

| Typical Dose | 250-1,000 mg/day | 300-1,000 mg/day | | NAD+ Increase | ~40-90% at standard doses | ~40-90% at standard doses | | Published Human Trials | ~15-20 completed | 40+ completed | | Key Advocate | David Sinclair (Harvard) | Charles Brenner (ChromaDex) | | Patent Protection | Fragmented, multiple suppliers | ChromaDex holds 90+ patents | | FDA Status | Reinstated as dietary supplement (Sept 2025) | Established dietary ingredient | | Leading Brand | Multiple (ProHealth, Renue, DoNotAge) | Tru Niagen (ChromaDex) | | Available Forms | Capsules, powder, sublingual | Capsules (primarily Tru Niagen) | | Stability | Relatively stable | Less stable than NMN in gut/blood | | Price Range | $0.50-2.50/day | $1.30-1.70/day (Tru Niagen) | | Niacin Flush Risk | None | None | | Flushing Side Effect | Rare, mild | Rare, mild |

Clinical Trial Evidence: NMN

#

The human clinical trial evidence for NMN has expanded rapidly since 2021:

Yoshino et al. (2021) — Insulin Sensitivity (PMID: 33888596) This was the first rigorous NMN trial published in Science. Researchers at Washington University gave 250 mg/day of NMN or placebo to 25 postmenopausal women with prediabetes for 10 weeks. The NMN group showed increased muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp), upregulated muscle insulin signaling pathways (AKT and mTOR phosphorylation), and increased expression of genes related to muscle remodeling. This was a landmark finding because it demonstrated a meaningful metabolic benefit in humans.

Yi et al. (2023) — Safety and Anti-Aging Review (PMID: 37619764) A comprehensive review of NMN human clinical trials confirmed that NMN supplementation has not triggered any adverse physiological effects across multiple studies and that oral doses up to 1,200 mg daily appear safe.

Morifuji et al. (2024) — Walking Speed and Sleep in Older Adults (PMC: 11336149) A 12-week, double-blind, randomized, placebo-controlled trial in healthy older adults (65-75 years) found that 250 mg/day of NMN maintained walking speed (the placebo group declined), improved sleep quality (lower Pittsburgh Sleep Quality Index scores for daytime dysfunction), and significantly increased blood NAD+ levels. No adverse effects were observed.

Huang et al. (2022) — Dose-Dependent Safety Trial (PMID: 36482258) A multicenter, double-blind, placebo-controlled trial randomized 80 healthy middle-aged adults to receive 300, 600, or 900 mg of NMN daily for 60 days. All doses were safe and well-tolerated, and NMN supplementation increased blood NAD+ concentrations in a dose-dependent manner.

Kim et al. (2022) — Exercise Performance (PMID: 35533066) NMN supplementation at 250 mg twice daily for 6 weeks improved aerobic capacity during exercise in healthy recreational runners. The NMN group showed enhanced oxygen utilization and ventilatory threshold compared to placebo.

Clinical Trial Evidence: NR

#

NR has a longer and deeper clinical trial history, largely due to ChromaDex’s investment in research:

Martens et al. (2018) — NAD+ in Healthy Older Adults (PMID: 29599478) A 2 x 6-week randomized, double-blind, placebo-controlled, crossover trial in 24 healthy middle-aged and older adults demonstrated that 1,000 mg/day of NR was well-tolerated and increased NAD+ levels in peripheral blood mononuclear cells. This was one of the first studies to confirm NR supplementation raises NAD+ in humans.

Dellinger et al. (2017) — NAD+ Dose Response (PMID: 29184669) A 3-arm trial in 115 healthy adults (60-80 years) randomized to NR plus pterostilbene (low dose: 250 mg NR + 50 mg pterostilbene; high dose: 500 mg NR + 100 mg pterostilbene) or placebo for 8 weeks. NR increased whole blood NAD+ by 40% in the low-dose group and 90% in the high-dose group in a dose-dependent manner.

Dollerup et al. (2018) — Obese Men Metabolic Trial (PMID: 30166321) A 12-week randomized, double-blind, placebo-controlled trial of 2,000 mg/day NR in 40 obese men found that NR was safe and effectively increased NAD+ metabolites, but did not produce significant changes in insulin sensitivity, resting energy expenditure, or body composition compared to placebo. This was an important “null” result that tempered expectations.

Brakedal et al. (2022) — Parkinson’s Disease (PMID: 35206326) A Phase I trial of 1,000 mg/day NR in 30 patients with newly diagnosed Parkinson’s disease showed that NR was safe, increased cerebral NAD+ (measured by MRI spectroscopy), and was associated with mild clinical improvement on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). This led to the ongoing Phase III NOPARK trial with 400 participants.

Remie et al. (2020) — Obese Adults Metabolic Outcomes (PMID: 33130565) A randomized, double-blind, placebo-controlled crossover trial of 1,000 mg/day NR for 6 weeks in 13 healthy obese adults. NR increased skeletal muscle NAD+ metabolites and induced anti-inflammatory gene expression changes, though it did not significantly alter mitochondrial respiration, insulin sensitivity, or body composition.

Elhassan et al. (2019) — Skeletal Muscle NAD+ (PMID: 30668119) NR supplementation (1,000 mg/day for 21 days) in healthy older adults increased NAD+ levels in skeletal muscle and blood, downregulated inflammatory pathways, and modulated the skeletal muscle acetylome. This provided direct evidence that oral NR reaches and affects muscle tissue.

What the Meta-Analyses Say

#

A 2025 systematic review and meta-analysis published in Aging Cell examined both NMN and NR across all published randomized controlled trials for effects on skeletal muscle mass and function (PMC: 12022230). The findings were sobering:

• NMN showed no significant effects on skeletal muscle index, handgrip strength, gait speed, or sit-to-stand test performance in pooled analysis.
• NR was associated with improved 6-minute walking distance in individuals with peripheral artery disease, but showed mixed results in other populations.
• Both consistently and significantly elevated blood NAD+ levels.

The takeaway: both NMN and NR reliably raise NAD+ levels in humans, but translating that biochemical change into measurable clinical outcomes like improved strength, endurance, or metabolic markers remains inconsistent. The most promising results have come from specific populations (prediabetic women for NMN, Parkinson’s patients for NR) rather than from healthy general populations.

Bioavailability: How Much Actually Gets In?

#

Oral NMN Absorption

#

A 2022 study confirmed that oral NMN administration is safe and efficiently increases blood NAD+ levels in healthy subjects, with NMN showing good gut stability (PMID: 35392820). NMN is described as being more stable than NR in both the gastrointestinal tract and blood, which is an advantage for oral supplementation.

However, the question of how much orally consumed NMN reaches cells intact versus being converted to NR first remains unresolved. The practical implication is that oral NMN does raise systemic NAD+ — the exact molecular route it takes to get there is of academic interest but may not matter much for the end user.

Sublingual NMN: Does It Matter?

#

Sublingual (under-the-tongue) NMN has gained popularity based on the theory that bypassing the gastrointestinal tract allows more NMN to enter the bloodstream intact. Some manufacturers market sublingual NMN as having “2-3 times higher bioavailability” than capsules.

The reality is more nuanced. A 2024 study in Nutrients reported that sublingual NMN showed approximately 2 times higher bioavailability than oral capsules. However, this was not a large-scale, peer-reviewed human clinical trial with the rigor of the studies described above. Capsules remain the only NMN delivery system tested repeatedly in randomized, placebo-controlled human trials. The sublingual route is plausible and may offer advantages, but the evidence is preliminary.

Other delivery forms — including liposomal NMN and enteric-coated capsules — are also marketed, but similarly lack robust clinical validation.

NR Oral Absorption

#

NR’s cell entry via equilibrative nucleoside transporters is well-characterized, and multiple clinical trials have confirmed that oral NR supplementation at 300-1,000 mg/day reliably increases blood and tissue NAD+ levels. One comparison of two separate human studies suggested that NR increased whole blood NAD+ by approximately 25% more than NMN after two weeks, though direct head-to-head trials are needed to confirm this.

A notable stability concern is that NR may be less stable than NMN in solution and in the GI tract, which is why ChromaDex uses the chloride salt form (nicotinamide riboside chloride, NRC) for improved stability. Tru Niagen capsules are specifically formulated to address this.

The FDA Regulatory Saga: NMN’s Rollercoaster

#

The 2022 Ban

#

In November 2022, the FDA removed NMN from the list of permitted dietary supplement ingredients. The rationale was not based on safety concerns but on a regulatory technicality: under the Federal Food, Drug, and Cosmetic Act, once a substance is authorized for investigation as a new drug, it generally cannot be simultaneously marketed as a dietary supplement. Because NMN had been the subject of an Investigational New Drug (IND) application, the FDA argued it was excluded from the supplement category.

This decision sent shockwaves through the supplement industry and left millions of NMN consumers in regulatory limbo. Major retailers pulled NMN products from their shelves, and the Natural Products Association (NPA) filed a lawsuit challenging the decision.

The 2025 Reversal

#

On September 29, 2025, the FDA reversed its position and confirmed that NMN is lawful for use in dietary supplements. The agency acknowledged that NMN was marketed as a dietary supplement in the United States as early as 2017 — before the IND authorization — and therefore met the statutory exception allowing continued supplement marketing.

However, NMN is now classified as a New Dietary Ingredient (NDI), meaning companies must submit a New Dietary Ingredient Notification (NDIN) to the FDA before marketing NMN products. This adds a layer of regulatory oversight that NR (which has had established dietary ingredient status for longer) does not face to the same degree.

In December 2025, the FDA further reinforced NMN’s NDI status with additional letters to ingredient suppliers, formalizing the premarket notification requirements.

What This Means for Consumers

#

NMN is legal to buy and sell as a supplement in the United States. However, the regulatory uncertainty of 2022-2025 highlighted a key risk: NMN’s legal status was less stable than NR’s. NR, backed by ChromaDex’s established FDA notifications and pharmaceutical-grade manufacturing, never faced the same regulatory threat. If regulatory certainty matters to you, NR has a slightly stronger track record on this front.

The Broader NAD+ Precursor Family

#

NMN and NR are not the only ways to raise NAD+ levels. Understanding the full family of precursors helps put the NMN vs NR debate in context.

Niacin (Nicotinic Acid, Vitamin B3)

#

Niacin is the oldest and cheapest NAD+ precursor. It enters the Preiss-Handler pathway and requires three enzymatic steps to become NAD+. Niacin is highly effective at raising NAD+ levels and has decades of clinical data supporting its use for cardiovascular health (particularly for raising HDL cholesterol and lowering triglycerides).

The major downside is the niacin flush — a dose-dependent skin flushing, warmth, and itching caused by prostaglandin D2 release in the skin. This flush is harmless but extremely uncomfortable for many people, and it limits niacin’s popularity as an NAD+ booster. Extended-release formulations reduce flushing but carry a small risk of liver toxicity.

Niacinamide (Nicotinamide)

#

Niacinamide is another form of vitamin B3 that enters the salvage pathway. It does not cause flushing, which is an advantage over niacin. However, its conversion to NMN requires the enzyme NAMPT, which is the rate-limiting step in the salvage pathway and becomes less efficient with age. Additionally, at higher doses, niacinamide can inhibit sirtuins — which is counterproductive if your goal is to activate these longevity-associated enzymes.

NAD+ IV Therapy

#

NAD+ can be administered directly via intravenous infusion, typically at doses of 250-750 mg per session. This delivers 100% bioavailability — every molecule goes directly into the bloodstream.

However, NAD+ IV therapy has significant limitations:

• Cost: $250 to $1,000+ per infusion, making it impractical for daily use
• Time: Each infusion takes 2-4 hours
• Discomfort: Many patients report nausea, chest tightness, and cramping during infusion
• Questionable cellular uptake: NAD+ is too large to cross cell membranes directly. Dr. Eric Verdin, President of the Buck Institute for Research on Aging, has stated that “NAD+ is too big to enter cells and is mostly broken down into nicotinamide when injected. Oral precursors like NMN or NR are a better bet for most people.”
• Limited evidence: There are far fewer controlled clinical trials for IV NAD+ than for oral NMN or NR

For most people, oral NMN or NR supplementation is more practical, affordable, and better supported by clinical evidence than NAD+ IV therapy.

Resveratrol Synergy

#

Resveratrol is a polyphenol found in grape skins, red wine, and Japanese knotweed. It is not itself a NAD+ precursor, but it activates SIRT1, the sirtuin most associated with longevity. Because sirtuins require NAD+ to function, the theory is that combining resveratrol with a NAD+ precursor like NMN creates a synergistic effect — resveratrol turns on the sirtuin “engine” while NMN provides the “fuel.”

David Sinclair takes 1 gram of resveratrol daily alongside his 1 gram of NMN, mixed in coconut yogurt (the fat enhances resveratrol absorption, as it is fat-soluble). Animal studies have shown promising synergy between resveratrol and NAD+ boosting, though no human clinical trial has directly tested the NMN + resveratrol combination against either compound alone.

Resveratrol alone has shown benefits for cardiovascular health, inflammation reduction, and blood sugar regulation in some human trials, though the evidence is mixed and doses in studies are often higher than what people typically supplement.

Clues Your Body Tells You: Signs of NAD+ Decline

#

One of the most important aspects of NAD+ supplementation is recognizing what your body is telling you — both the signs that you may benefit from boosting NAD+ and the signals that supplementation is working.

Signs That NAD+ Levels May Be Low

#

NAD+ decline is gradual, and you will not notice it like a sudden illness. Instead, it manifests as a slow accumulation of subtle changes that are easy to dismiss as “just getting older.” Watch for these patterns:

• Persistent fatigue that sleep does not fix: You get 7-8 hours of sleep but still wake up feeling unrefreshed. Your energy crashes mid-afternoon regardless of what you eat. This is a hallmark of mitochondrial dysfunction driven by low NAD+.
• Slower recovery from exercise: Workouts that used to leave you mildly sore for a day now take 3-4 days to recover from. Your muscles feel heavy and sluggish. This reflects impaired mitochondrial energy production and reduced cellular repair capacity.
• Brain fog and reduced mental clarity: Difficulty concentrating, word-finding problems, feeling like your thinking has “slowed down.” The brain is one of the most metabolically active organs and is highly sensitive to NAD+ depletion.
• Increased susceptibility to illness: Getting sick more frequently or recovering more slowly. NAD+ decline impairs immune cell function and the inflammatory response.

• Skin changes: Thinner, less elastic skin, slower wound healing, increased sun sensitivity. NAD+ is critical for DNA repair in skin cells, and its decline accelerates photoaging.
• Disrupted sleep patterns: Difficulty falling asleep, frequent waking, or poor sleep quality. NAD+ levels follow circadian rhythms, and disruption of NAD+ metabolism affects the sleep-wake cycle.
• Weight gain despite no change in diet or exercise: As mitochondrial efficiency drops, your body becomes less effective at burning fat and maintaining metabolic rate.
• Joint stiffness and increased aches: Low-grade chronic inflammation (inflammaging) driven by reduced sirtuin activity.

Signs That NAD+ Supplementation Is Working

#

If you start taking NMN or NR, here is what improvement typically looks like, based on clinical trial data and user reports:

Week 1-2:

• Subtle increase in morning energy — you may notice you wake up slightly more alert
• Blood NAD+ levels begin to rise (measurable by blood tests within 2 weeks)
• Some people report mild digestive adjustment (usually resolves within a few days)

Week 2-4:

• More consistent energy throughout the day, with less afternoon crash
• Improved exercise recovery — soreness resolves faster
• Sleep quality may begin improving, with less nighttime waking
• Mental clarity starts to sharpen, particularly in the late afternoon

Month 1-2:

• Noticeable improvement in physical endurance and stamina
• Skin may appear more hydrated and resilient
• Mood stability improves as neuroinflammation decreases
• Walking speed and grip strength may improve (as seen in the Morifuji et al. 2024 NMN trial)

Month 3-6:

• Sustained energy improvements become the “new normal”
• Exercise capacity at or above previous baseline
• Sleep architecture may normalize (deeper sleep, less waking)
• Metabolic markers may improve (fasting glucose, insulin sensitivity)

Warning Signs to Watch For

#

While both NMN and NR are well-tolerated, watch for these signals that something needs adjustment:

• Persistent headaches in the first week: Reduce your dose by 50% and increase slowly. This is the most common “too much too fast” signal.
• Overstimulation or anxiety: Some people, particularly those sensitive to B vitamins, may feel jittery or “wired.” Try taking your dose in the morning rather than afternoon, or reduce the dose.
• Digestive upset lasting more than a week: Switch brands (manufacturing impurities vary), try taking with food, or try a different form (e.g., sublingual instead of capsule).
• Skin flushing: Rare with NMN/NR (unlike niacin), but if it occurs, it may indicate a histamine response. Consider taking with food and starting at a lower dose.
• No effect after 8 weeks at adequate doses: This does not necessarily mean NAD+ levels are not rising — it may mean your baseline was not as depleted as expected, or that other factors (sleep, exercise, diet) are the limiting factor.

See a doctor if you experience: chest pain, significant heart rate changes, severe gastrointestinal symptoms, yellowing of the eyes or skin, or any allergic reaction (hives, difficulty breathing). These are extremely rare but warrant medical attention.

Dosing Protocols: NMN vs NR

#

NMN Dosing

#

Based on the published clinical trials:

Practical NMN protocol:

• Start: 250 mg/day for the first 2 weeks
• Assess: If well-tolerated, consider increasing to 500 mg/day
• Maintenance: Most people settle at 250-500 mg/day
• Timing: Morning, with or without food (some prefer on an empty stomach for faster absorption)
• Sinclair protocol: 1,000 mg NMN + 1,000 mg resveratrol (with fat source) + optional metformin

NR Dosing

#

Based on the published clinical trials:

Practical NR protocol:

• Start: 300 mg/day (one Tru Niagen capsule)
• Assess: If well-tolerated, consider increasing to 600-1,000 mg/day for stronger effect
• Maintenance: 300-1,000 mg/day depending on goals and budget
• Timing: Morning, with or without food
• Advanced protocol: 1,000 mg NR + quercetin or apigenin (CD38 inhibition)

Combining NMN/NR with CD38 Inhibitors

#

Because CD38 is the primary enzyme destroying NAD+ with aging, some longevity-focused protocols combine NAD+ precursors with natural CD38 inhibitors:

• Apigenin (50-100 mg/day): Found in chamomile, parsley, and celery. The study by Escande et al. (PMID: 23172919) showed apigenin inhibits CD38 and increases intracellular NAD+. Also promoted by Andrew Huberman for sleep benefits.
• Quercetin (500-1,000 mg/day): Found in onions, apples, and berries. Also inhibits CD38 and has broad anti-inflammatory properties. Some evidence for senolytic activity (clearing senescent cells) when combined with dasatinib.

The logic: boost NAD+ production (NMN or NR) while simultaneously reducing NAD+ destruction (apigenin or quercetin). This two-pronged approach has not been tested in a dedicated human clinical trial, but the mechanistic rationale is sound based on the individual studies.

Side Effects and Safety

#

NMN Safety Profile

#

Across all published human clinical trials, NMN has demonstrated a strong safety record:

• Doses up to 1,250 mg/day for 4 weeks showed no adverse effects in healthy men and women (PMID: 35927490)
• The most common reported side effects are mild and transient: occasional nausea, mild headache, mild digestive discomfort, and temporary flushing
• No liver toxicity, kidney toxicity, or significant blood chemistry changes observed
• No serious adverse events reported in any published trial

Theoretical concerns (not observed in trials but worth monitoring):

• Cancer risk: NAD+ fuels rapidly dividing cells, which theoretically includes cancer cells. No human evidence supports increased cancer risk from NMN supplementation, but people with active cancer should discuss NAD+ boosting with their oncologist.

• Methyl group depletion: High-dose NAD+ precursors may increase demand for methyl donors (like SAMe, folate, and B12) because the nicotinamide produced during NAD+ turnover must be methylated for excretion. Some practitioners recommend supplementing with trimethylglycine (TMG) or a B-complex when taking high-dose NMN.

NR Safety Profile

#

NR has an equally clean safety record with a slightly longer track record:

• Doses up to 2,000 mg/day for 12 weeks were safe and well-tolerated (PMID: 30166321)
• 1,000 mg/day is the most-studied dose and has been tested in multiple trials lasting 6-12 weeks with no safety signals
• Side effects are similar to NMN: occasional mild GI discomfort, headache, and nausea
• A comprehensive 2023 review in Science Advances of all NR supplementation studies concluded that NR is “safe and well tolerated” at tested doses (PMID: 37450599)

Drug Interactions

#

Both NMN and NR may interact with:

• Immunosuppressants: NAD+ influences immune function; discuss with your doctor if you take immunosuppressive medications
• Chemotherapy drugs: The theoretical concern about fueling cancer cell metabolism applies here
• Blood sugar medications: Both NMN and NR may affect insulin sensitivity; monitor blood sugar if you take metformin or insulin
• Blood thinners: No direct interaction known, but any new supplement should be discussed with your healthcare provider if you are on anticoagulation therapy

Cost Comparison

#

The cost equation for NMN vs NR depends heavily on which brands and forms you choose.

NMN Cost Breakdown

#

NR Cost Breakdown

#

Value Analysis

#

• Cheapest per milligram: Bulk NMN powder wins on raw cost, but you sacrifice quality assurance and third-party testing.
• Best quality assurance: Tru Niagen NR is the clear winner — patented ingredient, pharmaceutical-grade manufacturing, 90+ patents, and used in 65% of all registered NR clinical trials.
• Best overall value for NMN: ProHealth or DoNotAge capsules offer a reasonable balance of quality and price, with third-party testing available.
• If budget is no object: Tru Niagen Pro 1,000 mg provides the most clinically validated NR dose in a convenient single capsule.

Which Should You Choose?

#

Choose NMN If:

#

• You want to follow David Sinclair’s protocol: His 1g NMN + 1g resveratrol stack is the most well-known longevity protocol, and NMN is the cornerstone.
• You want to bypass the NAMPT bottleneck directly: NMN is one step closer to NAD+ in the biosynthesis pathway.
• You prefer more dosing flexibility: NMN is available in powder, capsule, sublingual, and liposomal forms from dozens of brands.
• Budget is a priority: Bulk NMN powder is generally cheaper per milligram than patented NR formulations.
• You are comfortable with the slightly less established regulatory history: NMN’s FDA status was in flux from 2022-2025 but is now resolved.

Choose NR If:

#

• You value the largest body of clinical evidence: NR has 40+ published clinical studies, including ongoing Phase III trials for Parkinson’s disease.
• You want pharmaceutical-grade quality assurance: Tru Niagen’s patented Niagen ingredient is the gold standard for standardized, tested NR.
• You prefer established regulatory status: NR has never faced the FDA regulatory challenges that NMN did.

• You want a proven cell entry mechanism: NR’s absorption via equilibrative nucleoside transporters is well-characterized and not disputed.
• You are looking at neurodegenerative disease protection: The NR-Parkinson’s research (NOPARK trial) is the most advanced clinical trial for any NAD+ precursor in a specific disease.

Consider Both (or Cycling) If:

#

• You want to cover all potential pathways of NAD+ replenishment
• You are already taking one and want to experiment with adding or switching
• You are pursuing an aggressive longevity protocol and want to maximize NAD+ through multiple entry points

#

Where to Buy Quality Supplements

#

Based on the research discussed in this article, here are some high-quality options:

• Protein Supplement
• Bcaa Supplement

The Bottom Line

#

There is no clear winner. If someone tells you NMN is definitively better than NR (or vice versa), they are either selling something or oversimplifying the science. Both molecules raise NAD+ levels effectively. Both are safe at studied doses. Both have promising but still-evolving human clinical trial data.

The honest assessment: NMN has more hype and a flashier spokesperson (Sinclair), while NR has more published clinical data and better quality control infrastructure (ChromaDex/Tru Niagen). For most people, either one at a consistent daily dose of 250-1,000 mg will meaningfully increase NAD+ levels.

What may matter more than which precursor you choose is the overall strategy: combine your NAD+ precursor with lifestyle factors that support NAD+ production (regular exercise, caloric restriction, circadian rhythm alignment) and compounds that reduce NAD+ consumption (apigenin or quercetin for CD38 inhibition). The supplement is one piece of a larger puzzle.

Common Questions About Nmn

#

What are the benefits of nmn?

Nmn has been studied for various potential health benefits. Research suggests it may support several aspects of health and wellness. Individual results can vary. The strength of evidence differs across different claimed benefits. More high-quality research is often needed. Always review the latest scientific literature and consult healthcare professionals about whether nmn is right for your health goals.

Is nmn safe?

Nmn is generally considered safe for most people when used as directed. However, individual responses can vary. Some people may experience mild side effects. It’s important to talk with a healthcare provider before using nmn, especially if you have existing health conditions, are pregnant or nursing, or take medications.

How much nmn should I take?

The appropriate dosage of nmn can vary based on individual factors, health goals, and the specific product formulation. Research studies have used different amounts. Always start with the lowest effective dose and follow product label instructions. Consult a healthcare provider for personalized dosage recommendations based on your specific needs.

What are the side effects of nmn?

Most people tolerate nmn well, but some may experience mild side effects. Common reported effects can include digestive discomfort, headaches, or other minor symptoms. Serious side effects are rare but possible. If you experience any unusual symptoms or reactions, discontinue use and consult a healthcare provider. Always inform your doctor about all supplements you take.

When should I take nmn?

The optimal timing for taking nmn can depend on several factors including its absorption characteristics, potential side effects, and your daily routine. Some supplements work best with food, while others are better absorbed on an empty stomach. Follow product-specific guidelines and consider consulting a healthcare provider for personalized timing recommendations.

Can I take nmn with other supplements?

Nmn is a topic of ongoing research in health and nutrition. Current scientific evidence provides some insights, though more studies are often needed. Individual responses can vary significantly. For personalized advice about whether and how to use nmn, consult with a qualified healthcare provider who can consider your complete health history and current medications.

How long does nmn take to work?

The time it takes for nmn to work varies by individual and depends on factors like dosage, consistency of use, and individual metabolism. Some people notice effects within days, while others may need several weeks. Research studies typically evaluate effects over weeks to months. Consistent use as directed is important for best results. Keep a journal to track your response.

Who should not take nmn?

Nmn is a topic of ongoing research in health and nutrition. Current scientific evidence provides some insights, though more studies are often needed. Individual responses can vary significantly. For personalized advice about whether and how to use nmn, consult with a qualified healthcare provider who can consider your complete health history and current medications.

Frequently Asked Questions

#

See the FAQ section in the page metadata for common questions about NMN vs NR.

Recommended Products

#

Related Articles

#

• [Multivitamin vs Individual Supplements: Which Is Better? [Complete Comparison Guide]](/comparisons/multivitamin-vs-individual-supplements/)
• 5-Htp vs L-Tryptophan For Mood: Which Is Better? [Complete Comparison Guide]
• [Apple Cider Vinegar vs Digestive Enzymes For Digestion: Which Is Better? [Complete Comparison Guide]](/comparisons/apple-cider-vinegar-vs-digestive-enzymes-for-digestion/)
• Bcaa vs Eaa: Which Is Better? [Complete Comparison Guide]
• [Berberine vs Metformin For Blood Sugar: Which Is Better? [Complete Comparison Guide]](/comparisons/berberine-vs-metformin-for-blood-sugar/)

References

#

1. Imai, S. I., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464-471. PMID: 24560926

2. Zhu, X. H., Lu, M., Lee, B. Y., Ugurbil, K., & Chen, W. (2015). In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences, 112(9), 2876-2881. PMID: 26458459

3. Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. PMID: 27304511

4. Escande, C., Nin, V., Price, N. L., et al. (2013). Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 62(4), 1084-1093. PMID: 23172919

5. Grozio, A., Mills, K. F., Yoshino, J., et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1(1), 47-57. PMID: 31131364

6. Schmidt, M. S., & Brenner, C. (2019). Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nature Metabolism, 1(7), 660-661. PMID: 32694648

7. Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. PMID: 33888596

8. Yi, L., Maier, A. B., Tao, R., et al. (2023). The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Advances in Nutrition, 14(6), 1416-1435. PMID: 37619764

9. Morifuji, M., Higashi, S., Ebihara, S., et al. (2024). Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. PMC: 11336149

10. Huang, P., Wang, M., Liu, Y., et al. (2022). The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1), 29-43. PMID: 36482258

11. Martens, C. R., Denman, B. A., Mazzo, M. R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286. PMID: 29599478

12. Dellinger, R. W., Santos, S. R., Morris, M., et al. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging and Mechanisms of Disease, 3, 17. PMID: 29184669

13. Dollerup, O. L., Christensen, B., Svart, M., et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition, 108(2), 343-353. PMID: 30166321

14. Brakedal, B., Dölle, C., Riber, F., et al. (2022). The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism, 34(3), 396-407. PMID: 35206326

15. Elhassan, Y. S., Kluckova, K., Fletcher, R. S., et al. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 28(7), 1717-1728. PMID: 30668119

16. Gomes, A. P., Price, N. L., Ling, A. J. Y., et al. (2013). Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 155(7), 1624-1638. PMID: 24331606

17. Bieganowski, P., & Brenner, C. (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell, 117(4), 495-502. PMID: 15137942

18. Remie, C. M. E., Roumans, K. H. M., Moonen, M. P. B., et al. (2020). Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. American Journal of Clinical Nutrition, 112(2), 413-426. PMID: 33130565